This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep 2026 quarter revenue and profit surge; auditor flags receivables
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone results for the quarter ended 30 September 2026 show revenue from operations of Rs 581.98 lakh versus Rs 157.63 lakh a year earlier and profit after tax of Rs 72.53 lakh versus Rs 6.75 lakh. Solar power revenue newly contributed Rs 99.81 lakh. Standalone half-year operating cash flow was negative Rs 58.28 lakh. The auditor highlighted Rs 574.16 lakh of over-one-year receivables without a loss provision.
Strong growth supports sentiment, but negative cash flow, aged receivables and proposed Rs 3 crore warrants raise credit and dilution risks.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹5.82 Cr | ₹1.58 Cr | +269.2% |
| Operating profit | ₹0.95 Cr | ₹0.03 Cr | +2,836.0% |
| Profit after tax | ₹0.73 Cr | ₹0.07 Cr | +974.5% |
| EBITDA margin | 17.8% | 2.1% | +15.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.